Maxim Group assumed coverage on shares of Artelo Biosciences (NASDAQ:ARTL) in a research note published on Tuesday morning, The Fly reports. The brokerage issued a buy rating and a $8.00 target price on the stock.

Shares of NASDAQ:ARTL opened at $3.90 on Tuesday. Artelo Biosciences has a 12-month low of $1.62 and a 12-month high of $10.50.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, an ethical biopharmaceutical company, focuses on developing, licensing, and commercializing cannabinoid therapeutic treatments. Its products pipeline includes ART12.11, a cannabidiol composition for the treatment of inflammatory bowel disease, stroke, and rare/orphan diseases; ART26.12, an endocannabinoid transport protein (FABP5) inhibitor for the treatment of breast cancer, prostate cancer, and neuropathic and nociceptive pain; and ART27.13 for the treatment of cancer and cachexia.

Further Reading: What is meant by a buy rating?

The Fly

Receive News & Ratings for Artelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.